{"id":8816,"date":"2025-12-03T23:02:21","date_gmt":"2025-12-03T23:02:21","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/12\/03\/hair-loss-drug-succeeds-phase-3-trial-cosmo-pharmaceuticals\/"},"modified":"2025-12-03T23:02:21","modified_gmt":"2025-12-03T23:02:21","slug":"hair-loss-drug-succeeds-phase-3-trial-cosmo-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/12\/03\/hair-loss-drug-succeeds-phase-3-trial-cosmo-pharmaceuticals\/","title":{"rendered":"STAT+: Hair loss drug succeeds in Phase 3, but data underwhelms experts"},"content":{"rendered":"<p>    STAT+: Hair loss drug succeeds in Phase 3, but data underwhelms experts<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p>A topical hair loss medication successfully built up hair in a Phase 3 trial, according to the results of two late-stage trials released Wednesday.\u00a0<\/p>\n<p>Cosmo Pharmaceuticals, which is based in Dublin, ran the studies on men with a common form of hair loss called androgenetic alopecia. <a href=\"https:\/\/www.cosmopharma.com\/news\/cosmo-announces-breakthrough-phase-iii-topline-results-from-scalp-1-and-scalp-2-for-clascoterone-5-solution-in-male-hair-loss-showing-up-to-539-relative-improvement-in-target-area-hair-count-vs-place\">The company reported<\/a> that men who used Cosmo\u2019s drug clascoterone had more hair after six months than the men in a placebo group \u2014 168% more hair in one trial and 539% in another.\u00a0<\/p>\n<p>Cosmo anticipates filing for regulatory approvals in the U.S. and Europe next year, after it gathers the full 12-month safety data in the spring.\u00a0<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/12\/03\/hair-loss-drug-succeeds-phase-3-trial-cosmo-pharmaceuticals\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Allison DeAngelis<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/12\/03\/hair-loss-drug-succeeds-phase-3-trial-cosmo-pharmaceuticals\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: Hair loss drug succeeds in Phase 3, but data underwhelms experts A topical hair loss medication successfully built up hair in a Phase 3 trial, according to the results of two late-stage trials released Wednesday.\u00a0 Cosmo Pharmaceuticals, which is based in Dublin, ran the studies on men with a common form of hair loss [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2194,2154,2155,2152],"tags":[2150],"class_list":["post-8816","post","type-post","status-publish","format-standard","hentry","category-biotech","category-biotechnology","category-pharmaceuticals","category-stat","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/8816"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=8816"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/8816\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=8816"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=8816"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=8816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}